Archives
-
Puromycin as a Lens on NSCLC Translation
2026-09-18
Puromycin dihydrochloride is more than a selection reagent: its ribosome-level mechanism can help translational researchers interrogate how protein synthesis supports inflammatory phenotypes in non-small cell lung carcinoma. This article connects pac-based cell engineering with the TRAIL receptor–IL-8 biology described in the reference study while defining the controls needed to avoid mistaking general cytotoxicity for pathway-specific insight.
-
(+)-Bicuculline: Practical GABAA Workflow
2026-09-18
This dossier-based guide explains how to prepare, store, and apply (+)-Bicuculline as a GABAA receptor antagonist for controlled neuroscience experiments. It is intended for research workflows involving GABAergic signaling and related neuronal readouts, not for diagnostic, clinical, or therapeutic use.
-
APEX-RNA-MS Maps RNA Modifications in Condensates
2026-09-17
Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a workflow that combines APEX2 proximity labeling with nucleoside LC-MS to profile modified RNA in defined cellular neighborhoods. The study identifies m6A and m5C enrichment near DNA damage foci and shows that modified tRNAs are associated with G3BP1-positive stress granules, providing a spatially resolved complement to RNA-modification and condensate studies.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-17
This FASEB Journal study develops a non-viral lipid nanoparticle system for delivering chemically modified p21 mRNA directly into bladder tumors. The work links localized protein replacement with restored cell-cycle control, DNA-damage signaling, apoptosis, and tumor suppression in an orthotopic mouse model.
-
Transcranial K+-Selective Channelrhodopsin for Seizures
2026-09-16
The reference study engineered HcKCR1-hs, a highly light-sensitive, moderately K+-selective channelrhodopsin, to enable neural inhibition through the intact skull. In mouse status epilepticus models, transcranial activation delayed seizure onset, improved survival, and reduced seizure activity, providing a preclinical framework for noninvasive optogenetic control of hyperexcitability.
-
Tioconazole Workflows for Fungal Research
2026-09-16
Tioconazole provides a practical, mechanism-led tool for in vitro antifungal assays, fungal infection models, and antifungal drug development. This guide combines formulation control, concentration screening, resistance-oriented experiments, and a careful comparison with metabolic-stress research in leukemia without overstating cross-domain evidence.
-
ATP Solution: Assay Design for mRNA Translation
2026-09-15
ATP Solution (100 mM) supports controlled kinase, transcription, ligation, and phosphorylation workflows. This article presents a decision-focused framework for connecting ATP quality and handling to the upstream assay requirements of p21 mRNA–LNP bladder cancer research.
-
Curcumol, Methionine Metabolism, and HSC Death
2026-09-15
The reference study identifies disrupted methionine metabolism as a mechanistic link between curcumol exposure, autophagy, and hepatic stellate cell death. Its rescue experiments with S-adenosylmethionine and loss-of-function studies targeting ATG7 provide a framework for testing metabolic control of fibrogenic cell survival.
-
N1-Methylpseudo-UTP: From Chemistry to Assay Design
2026-09-14
N1-Methyl-Pseudouridine-5'-Triphosphate can improve the performance of in vitro-transcribed RNA, but its greatest value emerges when translation, RNA quality, and reverse-transcription assays are interpreted together. This guide converts mechanistic evidence into practical experimental decisions for RNA translation mechanism research and mRNA development.
-
WM-8014: A Temporal Framework for KAT6A Assays
2026-09-14
WM-8014 is a potent KAT6A inhibitor for connecting enzyme inhibition with oncogene-induced senescence and cell-cycle phenotypes. This article presents a temporal, screen-to-compound framework for interpreting KAT6A biology and designing more informative cancer biology research assays.
-
GSK J4 HCl: JMJD3 Workflows for Chromatin Biology
2026-09-13
Build mechanism-first assays for H3K27 demethylation, cytokine regulation, and tumor biology with GSK J4 HCl. This guide connects decidual CXCL10 research to macrophage inflammation and K27M glioma workflows while emphasizing controls, exposure design, and troubleshooting.
-
Exo1 for Membrane Trafficking Assays
2026-09-12
Exo1 provides an acute, mechanistically distinct way to perturb Golgi–ER membrane traffic and measure downstream effects on exocytosis. This guide shows how to build concentration-response workflows, distinguish ARF1-dependent effects from broader Golgi disruption, and evaluate whether observations are relevant to tumor extracellular vesicle research without overstating the evidence.
-
OATP1B1 Disulfide Bonds Control Surface Function
2026-09-11
A 2026 study shows that all 16 extracellular cysteines of human OATP1B1 participate in eight disulfide bonds, with most bonds required for correct surface expression and transport activity. The findings clarify how cysteine variation may alter transporter biology while defining the limits of surface-labeling approaches for studying disulfide connectivity.
-
Angiotensin II: Mechanism & Research Guide
2026-09-11
Angiotensin II is an endogenous octapeptide and potent vasopressor that activates GPCR-linked vascular signaling. The peptide supports controlled hypertension mechanism study, vascular remodeling, and endothelial oxidative-stress research when concentration, exposure time, formulation, and model are matched to the experimental question.
-
Asymmetric Suzuki Synthesis of an Antimitotic Biaryl
2026-09-10
Herrbach and co-workers reported the first application of an atropo-enantioselective Suzuki cross-coupling to a biologically relevant axially chiral biaryl target related to rhazinilam. Screening of chiral phosphine and phosphetane ligands identified binaphthyl ligand 7a as a useful catalyst component, providing the nonbridged biaryl precursor with measurable enantioselectivity and establishing a practical route toward the biologically active atropisomer.